On Sept. 2, Pulmonem Inc., a Canadian biotechnology start-up, received Health Canada’s approval to begin Phase 3 clinical trials to test an oral medication to treat COVID-19. The treatment does not eliminate the need for a vaccine, but can potentially reduce the number of COVID-19 patients requiring hospitalization by diminishing[Read More…]
Tag: ri-muhc
McGill develops new screening method for Canada’s deadliest women’s cancer
Just hearing the “C” word is enough to send chills down anyone’s spine—and with cancer warnings splashed across everything from cigarette packages to coffee cups, it’s difficult to avoid. In 2017, the Canadian Cancer Society amassed over $80 million in donations. According to their 2017 report, 206,200 Canadians are expected[Read More…]
